Uptake of polymyxin B into renal cells

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 4200-4202

  Abdelraouf, Kamilia ^a,b   Chang, Kai Tai ^a   Yin, Taijun ^a   Hu, Ming ^a   Tam, Vincent H ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

GENTAMICIN; MEGALIN; NONESSENTIAL AMINO ACID; PIPERACILLIN; POLYMYXIN B; ANTIINFECTIVE AGENT;

ANIMAL CELL; APICAL MEMBRANE; ARTICLE; CELL SUSPENSION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG UPTAKE; FLUORESCENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CELL; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE CELL; LLC PK1 CELL LINE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ACTIVE TRANSPORT; ANIMAL; CELL LINE; CYTOLOGY; EPITHELIUM CELL; GRAM-NEGATIVE BACTERIAL INFECTIONS; KIDNEY PROXIMAL TUBULE; METABOLISM; MICROBIOLOGY; MULTIDRUG RESISTANCE; PIG;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; CELL LINE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EPITHELIAL CELLS; GRAM-NEGATIVE BACTERIAL INFECTIONS; KIDNEY TUBULES, PROXIMAL; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-2; POLYMYXIN B; SWINE;

EID: 84903156436     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02557-14     Document Type: Article

References (24)

1. Rice LB. 2007. Emerging issues in the management of infections caused by multidrug-resistant Gram-negative bacteria. Cleve. Clin. J. Med. 74(Suppl):S12-S20. http://dx.doi.org/10.3949/ccjm.74.Suppl-4.S12.
2. Giske CG, Monnet DL, Cars O, Carmeli Y. 2008. Clinical and economic impact of common multidrug-resistant Gram-negative bacilli. Antimicrob. Agents Chemother. 52:813-821. http://dx.doi.org/10.1128/AAC.01169-07. (Pubitemid 351358357)
3. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6:29-40. http://dx.doi.org/10.1038/nrd2201. (Pubitemid 46020284)
4. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. 2003. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant Gram-negative bacteria. Antimicrob. Agents Chemother. 47:2659-2662. http://dx.doi.org/10.1128/AAC.47.8.2659-2662.2003. (Pubitemid 36919476)
5. Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM, Kubin CJ. 2004. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J. Antimicrob. Chemother. 54:566-569. http://dx.doi.org/10.1093/jac/dkh369. (Pubitemid 39177490)
6. Akajagbor D, Wilson S, Shere-Wolfe KD, Dakum P, Charurat M, Gilliam BL. 2013. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin. Infect. Dis. 57:1300-1303. http://dx.doi.org/10.1093/cid/ cit453.
7. He J, Ledesma KR, Lam WY, Figueroa DA, Lim TP, Chow DS, Tam VH. 2010. Variability of polymyxin B major components in commercial formulations. Int. J. Antimicrobial Agents 35:308-310. http://dx.doi.org/10.1016/j.ijantimicag.2009. 11.005.
8. Abdelraouf K, He J, Ledesma KR, Hu M, Tam VH. 2012. Pharmacokinetics and renal disposition of polymyxin B in an animal model. Antimicrob. Agents Chemother. 56:5724-5727. http://dx.doi.org/10.1128/AAC.01333-12.
9. Abdelraouf K, Braggs KH, Yin T, Truong LD, Hu M, Tam VH. 2012. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob. Agents Chemother. 56:4625-4629. http://dx.doi.org/ 10.1128/AAC.00280-12.
10. Abdelraouf K, Chang K-T, Yin T, Hu M, Tam VH 2013. Uptake of polymyxin B into renal cells, abstr. A-1041, p 142. Abstr. 53rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
11. He J, Gao S, Hu M, Chow DS, Tam VH. 2013. A validated ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies. J. Antimicrob. Chemother. 68:1104-1110. http://dx.doi.org/10.1093/jac/dks536.
12. Dagil R, O'Shea C, Nykjaer A, Bonvin AM, Kragelund BB. 2013. Gentamicin binds to the megalin receptor as a competitive inhibitor using the common ligand binding motif of complement type repeats: insight from the NMR structure of the 10th complement type repeat domain alone and in complex with gentamicin. J. Biol. Chem. 288:4424-4435. http://dx.doi.org/10.1074/jbc.M112.434159.
13. Moestrup SK, Cui S, Vorum H, Bregengard C, Bjorn SE, Norris K, Gliemann J, Christensen EI. 1995. Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J. Clin. Invest. 96:1404-1413. http://dx.doi.org/10.1172/JCI118176.
14. Kubin CJ, Ellman TM, Phadke V, Haynes LJ, Calfee DP, Yin MT. 2012. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J. Infect. 65:80-87. http://dx.doi.org/10.1016/j.jinf.2012. 01.015.
15. Miyajima Y, Hiramatsu K, Mizukami E, Morinaga R, Ishii H, Shirai R, Kishi K, Tokimatsu I, Saikawa T, Kadota J. 2008. In vitro and in vivo potency of polymyxin B against IMP-type metallo-beta-lactamase-producing Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 32:437-440. http://dx.doi.org/10.1016/j. ijantimicag.2008.05.006.
16. Zavascki AP, Goldani LZ, Li J, Nation RL. 2007. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J. Antimicrob. Chemother. 60:1206-1215. http://dx.doi.org/10.1093/jac/dkm357. (Pubitemid 350168315)
17. Furtado GH, d'Azevedo PA, Santos AF, Gales AC, Pignatari AC, Medeiros EA. 2007. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 30:315-319. http://dx.doi.org/10.1016/j.ijantimicag.2007.05.017. (Pubitemid 47361713)
18. Gstraunthaler G, Pfaller W, Kotanko P. 1985. Biochemical characterization of renal epithelial cell cultures (LLC-PK1 and MDCK). Am. J. Physiol. 248:F536-F544. (Pubitemid 15056869)
19. Handler JS. 1983. Use of cultured epithelia to study transport and its regulation. J. Exp. Biol. 106:55-69. (Pubitemid 14200306)
20. Nielsen R, Birn H, Moestrup SK, Nielsen M, Verroust P, Christensen EI. 1998. Characterization of a kidney proximal tubule cell line, LLC-PK1, expressing endocytotic active megalin. J. Am. Soc. Nephrol. 9:1767-1776. (Pubitemid 28443473)
21. Kerjaschki D, Farquhar MG. 1982. The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc. Natl. Acad. Sci. U. S. A. 79:5557-5561. http://dx.doi.org/10.1073/pnas.79. 18.5557. (Pubitemid 13197683)
22. Chatelet F, Brianti E, Ronco P, Roland J, Verroust P. 1986. Ultrastructural localization by monoclonal antibodies of brush border antigens expressed by glomeruli. I. Renal distribution. Am. J. Pathol. 122:500-511. (Pubitemid 16017671)
23. Schmitz C, Hilpert J, Jacobsen C, Boensch C, Christensen EI, Luft FC, Willnow TE. 2002. Megalin deficiency offers protection from renal aminoglycoside accumulation. J. Biol. Chem. 277:618-622. http://dx.doi.org/10.1074/jbc. M109959200. (Pubitemid 34952099)
24. Suzuki T, Yamaguchi H, Ogura J, Kobayashi M, Yamada T, Iseki K. 2013. Megalin contributes to kidney accumulation and nephrotoxicity of colistin. Antimicrob. Agents Chemother. 57:6319-6324. http://dx.doi.org/10.1128/AAC.00254- 13.